Arthritis, rheumatoid pharmaceuticals

In this chapter, Case study levels 1 and 2 both explore the management of a single patient with rheumatoid arthritis. Rheumatoid arthritis is a frequently encountered condition with a large number of pharmaceutical treatment options. Creating two cases using the one patient allows a more detailed examination of the management of these patients. 

Damage to connective caused by leakage of elastases leads to damage associated with inflammatory diseases, such as pulmonary emphysema, adult respiratory distress syndrome, septic shock, cystic fibrosis, carcinogenesis, chronic bronchitis, and rheumatoid arthritis. Compounds that directly inhibit elastase or its release from human neutrophils are of enormous pharmaceutical and cosmetological interest in the development of new anti-inflammatory drugs. A possible source for elastase inhibitors are the medicinal Asteraceae and Droseraceae, particularly those used as traditional medicine in Asia. 

It is of special interest that rheumatoid arthritis is one of the first examples of the extensive antioxidant treatment of human patients. In previous years the most recommended pharmaceutical antioxidant agent has been SOD. In 1986, Wilsman [245] reviewed the results of 10 years of presumably successful clinical experience with CuZnSOD treatment of inflammatory disorders including RA. Niwa et al. [246] recommended the application of liposomal... 

The same principle was later applied by scientists at Immunex to enhance the pharmaceutical properties of the tumor necrosis factor receptor (TNFr), which, like CD4, is rapidly cleared from blood. The hybrid TNFr-Fc molecule (-150 kDa), which is now known as Enbrel, is used to reduce the inflammatory responses of rheumatoid arthritis [33,34]. The hybrid TNFr-Fc bas extended the plasma half-life of TNFr from several minutes to 190 hours. 

Compared with the above examples, whereby an array of pharmaceutically important molecules have been synthesized under pressure-driven flow, Garcia-Egido et al. (2002) reported the synthesis of fanetizole (207), an active compound for the treatment of rheumatoid arthritis, utilizing EOF. Employing a borosilicate glass microreactor fabricated at The University of Hull, the authors demonstrated the first example of a heated EOF-controlled reaction. As Scheme 60 illustrates, using... 

The markets for ARA and DHA are now well established in Europe and the United Stated and are clearly being developed in Japan as well as in China. The next PUFA that appears likely to be produced is EPA, which could be used as a nutraceutical for over-the-counter sales or, more likely, as a possible pharmaceutical, as there have been numerous reports of its benefits for the treatment of various diseases and disorders. Such conditions as atherosclerosis, cancer, rheumatoid arthritis, psoriasis, bipolar disorder, schizophrenia, and Alzheimer s disease have all been said to have been improved or relieved by the oral administration of EPA, sometimes on its own, although sometimes with DHA (34, 70-72). EPA and DHA, of course, occur together in many fish oils, and when treatment with both these PUFAs is advocated, then the use of fish oils would seem to be the appropriate recommendation. 

Hench P S et al 1949 The effect of a hormone of the adrenal cortex (17-hydroxy-ll-dehydrocorticosterone Compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis. Proceedings of the Staff Meetings of the Mayo Clinic 24 181,277 (acute rheumatism). The classic studies of the first clinical use of an adrenocortical steroid in inflammatory disease. See also page 298 for an account by E C Kendall of the biochemical and pharmaceutical background to the clinical studies. Kendall writes of his collaboration with Hench, he can now say "17-hydroxy-ll-dehydrocorticosterone" and in turn I can say "the arthritis of lupus erythematosus". In sophisticated circles, however, I prefer to say, "the arthritis of L.E. ". 

In aiming to further improve population association studies, MiUennium Pharmaceuticals is building a database containing large-scale registers of patients suffering from rheumatoid arthritis, multiple myelo-... 

---